The ASH 2024 conference featured industry leaders discussing the future of blood cancer treatment, emphasizing the potential for cures using innovative therapies. Data presented highlighted the disparities in access to bone marrow transplants for AML patients from disadvantaged backgrounds. Research on 9/11 first responders revealed a higher risk of blood cancers due to toxic exposure, with potential new treatment targets identified. Pfizer’s sudden withdrawal of a sickle cell drug was criticized as being “tone deaf” by experts, highlighting systemic flaws in treating this neglected disease. The panel discussed the need for humility and understanding when entering the sickle cell space.
Source link
ASH 2024: Roundup of news from second day of conference
